Argenta Revenue and Competitors

NZ

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Argenta's estimated annual revenue is currently $95.3M per year.(i)
  • Argenta's estimated revenue per employee is $201,000

Employee Data

  • Argenta has 474 Employees.(i)

Argenta's People

NameTitleEmail/Phone
1
Chief Financial OfficerReveal Email/Phone
2
CIO / Head Global Technology & EIReveal Email/Phone
3
CEOReveal Email/Phone
4
Head Project Management (Remote)Reveal Email/Phone
5
Head Clinical OperationsReveal Email/Phone
6
General CounselReveal Email/Phone
7
Head Health, Safety, Security & EnvironmentReveal Email/Phone
8
Head Technical ServicesReveal Email/Phone
9
Head Pharmaceutical Sciences (NZ)Reveal Email/Phone
10
Purchasing OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$24.3M1215%N/AN/A
#2
$18.9M94-3%N/AN/A
#3
$62.7M3124%N/AN/A
#4
$95.3M474N/AN/AN/A
#5
$148.9M7414%N/AN/A
#6
$14.7M730%N/AN/A
Add Company

What Is Argenta?

Argenta: A Pharmaceutical CRO and CMO Dedicated to Animal Health Argenta offers a full range of contract services - from pre-clinical development through to commercial product manufacture and more. Our products and services are exported to more than 36 countries, including the United States, Canada, Europe and Japan. Founded in 2006, with the combination of a successful pharmaceutical CRO and CMO, Argenta brings a substantial contract manufacturing facility and pharmaceutical research and development expertise together in one dynamic company. Argenta specializes in animal health. Our operations are purpose-built for the creation of animal health products. Everything is targeted to the specific needs of this market– from our understanding of the problem, approaches to the solution, and the provision of manufactured products once commercialized. Our vision is simple: Touching lives all over the world with the creation, development and production of the best animal health technologies and products. To do this, Argenta strives to be both price-competitive and second-to-none in the service and quality of our products - whether they are veterinary manufacturing solutions, or animal health research data destined for inclusion in regulatory submissions. Also vital to our success is the assurance our clients have that their intellectual property (IP) is carefully protected by Argenta. Health & safety and environmental responsibility are also important factors that impact on how we conduct our business. We're fresh. We're talented. We make things happen. Business Model Argenta is involved from opportunity assessment through to the commercial manufacture of pharmaceutical products for global supply.

keywords:N/A

N/A

Total Funding

474

Number of Employees

$95.3M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Argenta News

2022-04-20 - People Moves: Lloyd’s Names Hernandez Mkt. Dev. Mgr., Central America; Chaucer Taps Argenta’s Sheppard for Renewables; H.W. Kaufman Promotes Kaufman Davis

... Names Hernandez Mkt. Dev. Mgr., Central America; Chaucer Taps Argenta's Sheppard for Renewables; H.W. Kaufman Promotes Kaufman Davis. April 22, 2022.

2022-04-20 - People Moves: Lloyd’s Names Hernandez Mkt. Dev. Mgr., Central America; Chaucer Taps Argenta’s Sheppard for Renewables; H.W. Kaufman Promotes Kaufman Davis

... Names Hernandez Mkt. Dev. Mgr., Central America; Chaucer Taps Argenta's Sheppard for Renewables; H.W. Kaufman Promotes Kaufman Davis. April 22, 2022.

2022-04-17 - Argenta Appoints Will Downie As CEO

Will Downie succeeds interim CEO Stephen Sibson, who will resume his role as Argenta's Global Head of Manufacturing. “I am delighted to have...

2022-04-17 - Argenta Appoints Will Downie As CEO

Will Downie succeeds interim CEO Stephen Sibson, who will resume his role as Argenta's Global Head of Manufacturing. “I am delighted to have...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$145.2M474-4%N/A
#2
$119.1M47423%N/A
#3
$145.2M474-34%N/A
#4
$171.8M4747%N/A
#5
$15M474N/AN/A